AbCellera Biologics Inc. (ABCL)


-0.07 (-1.47%)
Symbol ABCL
Price $4.7
Beta 0.012
Volume Avg. 2.01M
Market Cap 1.360B
Shares () -
52 Week Range 4.67-14.97
1y Target Est -
DCF Unlevered ABCL DCF ->
DCF Levered ABCL LDCF ->
ROE -6.05% Neutral
ROA -4.81% Neutral
Operating Margin -
Debt / Equity 7.03% Neutral
P/E -18.08 Strong Sell
P/B 1.14 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest ABCL news

Dr. Carl L.G. Hansen Ph.D.
NASDAQ Global Select

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.